U.S. Markets closed

Roche Holding AG (RHHBY)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
32.575+0.10 (+0.32%)
At close: 3:59PM EDT
People also watch
NVSSNYNSRGYAZNBAYRY
Full screen
Previous Close32.470
Open32.600
Bid0.000 x
Ask0.000 x
Day's Range32.510 - 32.760
52 Week Range25.250 - 36.820
Volume956,231
Avg. Volume1,481,364
Market Cap213.73B
Beta0.51
PE Ratio (TTM)22.78
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.03 (3.14%)
Ex-Dividend Date2017-03-15
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacksyesterday

    Roche's (RHHBY) Combination Cancer Remedy Wins FDA Approval

    Roche (RHHBY) announced that the FDA has granted approval to the subcutaneous injection of its marketed lymphoma drug MabThera/Rituxan as Rituxan Hycela for the treatment of adults with different types of blood cancers.

  • Zacksyesterday

    The Zacks Analyst Blog Highlights: Novartis, Roche, Shire, Neos and Novo Nordisk

    The Zacks Analyst Blog Highlights: Novartis, Roche, Shire, Neos and Novo Nordisk

  • Reuters2 days ago

    New Roche haemophilia drug prevents bleeds but questions remain

    Roche's investigational haemophilia drug emicizumab cut the bleed rate by 87 percent in patients with resistance to standard therapy compared with those who received another treatment, the Swiss company said on Monday. Roche is counting on emicizumab to wrest a share of the $11 billion-a-year haemophilia drug market now dominated by traditional treatments from Novo Nordisk and Shire . Some analysts called Monday's data release convincing, with Jefferies saying it underpinned its $5 billion peak sales estimate for the medicine.